Competition heats up for insulin biosimilar market, scientist says

Competition heats up for insulin biosimilar market, scientist says

August 6, 2014 – With the EMA’s CHMP recommending approval for a new insulin biosimilar early last month, some in the industry are expecting an increasingly competitive field moving forward. Dr. Marcus Hompesch, President and CEO of Profil Institute for Clinical Research, Inc., told Biopharma-Reporter.com that the market seems ripe to grow as he’s seeing an uptick in clinical trials around insulin biosimilar.
Read the full article at Biopharma-Reporter.com »